Edgar Filing: CYTOKINETICS INC - Form 4

CYTOKIN Form 4 January 04,										
	ЛЛ							-	PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							N OMB Number:	3235-0287		
Check t if no lor subject Section Form 4	to STATEN 16.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSH SECURITIES							January 31, 2005 average urs per . 0.5	
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 5 obligations may continue. See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> GAGE L PATRICK						5. Relationship o Issuer				
(Last)	(First) (3. Date of Earliest Transaction				(Check all applicable)			
(Last) (First) (Middle) 280 EAST GRAND AVENUE			(Month/Day/Year) 01/02/2013			X_ Director 10% Owner Officer (give title Other (specify below) below)				
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting				
	CO, CA 94080						Person			
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution D any (Month/Day	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	port on a separate line	e for each clas	ss of secu	urities bene	ficially own	ned directly of	or indirectly.			
					inforn requir	nation cont ed to respo lys a curre	spond to the colle cained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and A
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying S
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4

Edgar Filing: CYTOKINETICS INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title
Non-Qualified Stock Option (right to buy)	\$ 0.6702	01/02/2013		А	223,813	02/02/2013(1)	01/02/2023	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 0.91					06/22/2012 <u>(3)</u>	05/22/2022	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 0.98					02/03/2012(4)	01/03/2022	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 1.44					06/18/2011 <u>(5)</u>	05/18/2021	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 2.16					02/03/2011 <u>(6)</u>	01/03/2021	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 2.81					06/20/2010 <u>(7)</u>	05/20/2020	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 3.33					12/05/2009 <u>(8)</u>	11/05/2019	Common Stock

Reporting Owners

Reporting Owner Name / Address	Relationships					
1 0	Director	10% Owner	Officer	Other		
GAGE L PATRICK 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CA 94080	Х					
Signatures						
By: Sharon A. Barbari For: L. Patrick Gage	(01/04/2013				
**Signature of Reporting Person		Date				

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Edgar Filing: CYTOKINETICS INC - Form 4

- (1) This option shall vest and become exercisable as to 223,813 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2014.
- (2) This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of \$60,000.
- (3) This option shall vest and become exercisable as to 25,000 shares divided into equal monthly installments such that the option shall be 100% vested on May 22, 2013.
- (4) This option shall vest and become exercisable as to 102,040 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2013.
- (5) This option shall vest and become exercisable as to 20,000 shares divided into equal monthly installments such that the option shall be 100% vested on May 18, 2012.
- (6) This option shall vest and become exercisable as to 46,296 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2012.
- (7) This option shall vest and become exercisable as to 20,000 shares divided into equal monthly installments such that the option shall be 100% vested on May 20, 2011.
- (8) This option shall vest and become exercisable as to 833 shares on 12/05/09 and the balance of 29,167 divided into equal monthly installments thereafter such that the option shall be 100% vested on 11/05/12.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.